CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Professor Mona Nada, Coordinator of the Headache Unit, Cairo University, Egypt Before the approval of anti-CGRP therapies for migraine, clinicians in Egypt faced a lot of unmet needs in migraineurs. Egypt, an Arab African country that links the Middle East and North Africa, has a population of about 103 million people, and a survey carried out …
Read more »Fernando Kowacs, Professor of Neurology, Universidade Federal de Ciências da Saude de Porto Alegre, Brazil. The migraine treatment landscape in Brazil has started to change following the arrival of the CGRP monoclonal antibodies (mAbs) but there is a long way to go before this new class of prophylactic therapy is available or accessible to all …
Read more »Jasem Al-Hashel, Consultant Neurologist and Associate Professor of Neurology, Faculty of Medicine, Kuwait University, Kuwait Migraine is prevalent in Kuwait and is associated with a significant socioeconomic burden.1,2 In a community-based study of 15,523 patients aged 18-65 years, 23% were diagnosed with episodic headache, 5.4% with chronic migraine and 2.4% with medication overuse headache.1 The …
Read more »László Vécsei, Professor of Neurology and Head of the Neuroscience Research Group, Albert Szent-Györgyi Clinical Center, University of Szeged, Hungary. Three anti-CGRP mAbs are currently approved for use in Hungary, and we have seen excellent responses in some patients, no response in a small number and a very good response in the rest. However, due …
Read more »Byung-Kun Kim, Eulji University School of Medicine, Seoul, South Korea Emgality (galcanezumab) was approved in South Korea in September 2019 and remains the only CGRP therapy available. Between December 2019, when it became available, and July 2020, I prescribed galcanezumab to around 200 patients, 55% of whom had chronic migraine, 40% episodic migraine (high frequency 31%, …
Read more »Richard J Stark, Alfred Hospital and Monash University, Melbourne, Australia. In Australia we have had the opportunity to treat a limited number of patients with erenumab, galcanezumab and fremanezumab. Each of the companies marketing these agents has produced a scheme enabling subsidised use: patient familiarisation programmes for erenumab and fremanezumab (each limited to 10 patients …
Read more »Joost Haan, Leiden University Medical Center and the Alrijne Hospital Leiderdorp, The Netherlands. In The Netherlands, erenumab, fremanezumab and galcanezumab are all available to clinicians and, as insurers do not as yet pay for these drugs, all three manufacturers run unmet need programmes through which patients with high frequency migraine can receive free treatment. Erenumab …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
